

Claims:

1. Use of a substance selected from Follicle Stimulating Hormone (FSH) and FSH variant for the preparation of a pharmaceutical composition for the treatment and/or the reduction of gamete chromosomal alterations in a male.

2. Use according to claim 1 wherein the gamete chromosomal alterations are numerical alterations.

3. Use according to claims 1 or 2 wherein the gamete numerical chromosomal alterations is spermatozoa diploidy.

4. Use according to any of the preceding claims wherein the gamete numerical chromosomal alterations is sexual chromosome disomy.

5. Use according to any of the preceding claims wherein the male is human.

6. Use according to any of the preceding claims wherein the substance is FSH.

7. Use according to any of the preceding claims wherein the substance is rFSH.

8. Use according to any of the preceding claims wherein the substance is administered on alternate days.

9. Use according to any of the preceding claims wherein the substance is administered at or about 75 to 300 IU/dose.

10. Use according to any of the preceding claims wherein the substance is administered at or about 150 IU/dose.

11. Use according to any of the preceding claims wherein the substance is rFSH and the human male is suffering from gamete aneuploidy.